New Drug Reducing Progression of Primary Progressive MS

In this video from the Vall d’Hebron Barcelona Hospital Campus, Dr. Xavier Montalbán talks about the Phase 3 international study of a new drug developed by Roche called ocrelizumab.  The clinical trials have shown that patients with primary progressive multiple sclerosis (PPMS) see a reduction of clinical progression in at least 12 weeks.

The U.S. Food and Drug Administration is giving priority review to a request to approve ocrelizumab as a treatment for PPMS. Read more here.

The new drug gives much hope for those who live with this relatively rare form of multiple sclerosis.

Ocrelizumab is a humanized monoclonal antibody under clinical investigation and development by the Swiss pharmaceutical company Roche. Read more here.

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.


  1. Kathleen Anderson says:

    I cannot afford the medicine as I am not on a drug plan; is there a way I can get it on a trial? I have PPMS, since 1994

  2. Jeanine Shahin says:

    It may be covered on the medical portion of your insurance since it will have to be administered in a hospital or infusion center setting.

Leave a Comment

Your email address will not be published. Required fields are marked *